

Synthesis and biological evaluation of fatty imidazolines

T. Satyavani · Y. Mohini · M. S. L. Karuna · R. B. N. Prasad ·
C. Ganesh Kumar · M. Poornima · P. Sujitha

Received: 9 October 2013 / Accepted: 3 February 2014
© Springer Science+Business Media New York 2014

Abstract A series of eight fatty imidazolines were synthesized under microwave-assisted conditions using different fatty acids namely octyl, decyl, dodecyl, tetradecyl and octadecyl, mixed fatty acids prepared from *Sterculia foetida* (containing cyclopropene-rich fatty acids), coconut (containing medium-chain-rich fatty acids), palm (containing saturated-rich fatty acids) and sunflower (containing unsaturated-rich fatty acids). Coconut, sunflower and non-edible oil *S. foetida*-based imidazolines were synthesized for the first time. The fatty imidazolines were evaluated for anti-fungal activity and found to be good to excellent (MIC, 4.68–18.75 $\mu\text{g ml}^{-1}$) against the tested *Candida* strains as compared with fluconazole (MIC, 16–64 $\mu\text{g ml}^{-1}$) as standard. The fatty imidazolines also exhibited excellent to moderate anti-bacterial activity (MIC, 4.68–75 $\mu\text{g ml}^{-1}$) against *Staphylococcus aureus* MTCC 96, *S. aureus* MLS 16 MTCC 2940 and *Pseudomonas aeruginosa* MTCC 2453 as compared with neomycin (MIC, 18.75 $\mu\text{g ml}^{-1}$) as standard. The cytotoxic evaluation of the imidazolines against different cancer cell

lines such as HeLa (Human Cervical Cancer Cell line), A549 (Human Alveolar Adenocarcinoma Cell line), MDA-MB-231 & MCF7 (Human Breast Adenocarcinoma Cell line) and Neuro2a (Mouse neuroblastoma cell line) showed excellent cytotoxicity for dodecyl (**3b**), tetradecyl (**3c**), octadecyl (**3d**) and coconut (**3f**)-based imidazolines. Sunflower-based imidazoline (**3g**) exhibited good anti-cancer activity towards A549, Neuro2a and palm-based imidazoline (**3h**) towards HeLa, A549 and MCF-7 cell lines.

Keywords Fatty acids · Fatty imidazolines · Anti-microbial agents · Cytotoxicity · Anti-cancer agents

Introduction

There has been a remarkable progress in the prevention, control and even eradication of infectious diseases with the development of novel anti-microbial drugs and vaccines. However, there has been a constant threat to the new drugs developed due to increase in the microbial resistance and evolution of newer microbial strains. The impact of the diseases emerging and re-emerging in tropical countries like India was found to be more during the past three decades. Cancer is one such disease, which is increasing day-by-day globally. The control of cancer requires effective implementation of knowledge by carrying out more and more research on bioactive compounds.

In this context, all substituted imidazolines exhibited a vast array of pharmacological properties such as anti-parasitic (Mukherjee *et al.*, 1989; Popa *et al.*, 2001), anti-fungal (Norman *et al.*, 1986) and anti-microbial (Khabnadideh *et al.*, 2003) activities. Their simple structures are known to possess inhibitory effects on microsomal oxidations (Wilkinson and Hetnarski, 1974), cytotoxic (Miller

Electronic supplementary material The online version of this article (doi:10.1007/s00044-014-0936-x) contains supplementary material, which is available to authorized users.

T. Satyavani · Y. Mohini · M. S. L. Karuna ·
R. B. N. Prasad (✉)
Centre for Lipid Research, CSIR-Indian Institute of Chemical
Technology, Uppal Road, Hyderabad 500 007, India
e-mail: rbnprasad@iict.res.in

C. G. Kumar · M. Poornima · P. Sujitha
Medicinal Chemistry and Pharmacology Division, CSIR-Indian
Institute of Chemical Technology, Uppal Road,
Hyderabad 500 007, India

Table 1 Anti-bacterial activity of fatty imidazolines **3a–h**

Compounds	Minimum Inhibitory concentration (MIC, $\mu\text{g ml}^{-1}$)		
	<i>S. aureus</i> MTCC 96	<i>S. aureus</i> MLS 16 MTCC 2940	<i>P. aeruginosa</i> MTCC 2453
3a	— ^a	—	—
3b	18.75	37.5	75
3c	4.68	4.68	18.75
3d	18.75	4.68	75
3e	75	—	75
3f	75	37.5	37.5
3g	4.68	4.68	4.68
3h	4.68	18.75	18.75
Imidazole	—	—	—
Neomycin	18.75	18.75	18.75

^a No activity

reaction between the fatty acid and the amine, resulting in the formation of fatty imidazoline ring. The synthesized molecules in the present study were further characterized using FTIR, ¹H NMR and ESI-MS studies. Although in some earlier studies, fatty acids such as lauric, myristic, palmitic and stearic acids (Palou *et al.*, 2003) and palm fatty acids-based imidazolines (Bajpai and Tyagi, 2007) were synthesized under microwave-assisted conditions. However, the biological evaluation of these fatty acid-based imidazolines was not reported. Hence, in the present study, those compounds having varied chain lengths and nature of the fatty acids were further evaluated for anti-microbial and anti-cancer activities for the first time. Among the different fatty acid-based imidazolines tested, compounds **3c**, **3d**, **3g** and **3h** exhibited excellent anti-bacterial activities (MIC value of $4.68 \mu\text{g ml}^{-1}$) towards *Staphylococcus aureus* MTCC 96, *S.*

aureus MLS 16 MTCC 2940, *Pseudomonas aeruginosa* MTCC 2453 as compared with the standard, neomycin (MIC value of $18.75 \mu\text{g ml}^{-1}$) (Table 1). The different fatty acid-based imidazolines prepared, including dodecyl fatty acid (**3b**), which is a medium-chain fatty acid, coconut-based with medium-chain-rich fatty acid mixture (**3f**) and *Sterculia* (with unusual cyclopropene fatty acid) (**3e**) exhibited poor activity which suggested that the medium-chain fatty acids and cyclopropene fatty acids were poor anti-bacterial agents.

The anti-*Candida* activity of *Sterculia* containing cyclopropene-rich fatty acid-based imidazolines (**3e**) showed promising activity (MIC value of $4.68 \mu\text{g ml}^{-1}$) towards *C. albicans* MTCC 183. The activity was found to be eight times more potent as compared with fluconazole (MIC value of $32 \mu\text{g ml}^{-1}$). While, the compounds **3b**, **3c**, **3g** and **3h** exhibited good anti-*Candida* activity (MIC value of $18.75 \mu\text{g ml}^{-1}$) against the tested *C. albicans* MTCC 3958, *C. albicans* MTCC 7315, *C. parapsilosis* MTCC 1744, *C. albicans* MTCC 4748, *C. glabrata* MTCC 3019 and moderate activity (MIC value of $37.5 \mu\text{g ml}^{-1}$) towards *C. albicans* MTCC 7315, *C. albicans* MTCC 1637, *C. albicans* MTCC 227, *C. parapsilosis* MTCC 1744 and *C. glabrata* MTCC 3019 as compared with the standard drug, fluconazole (MIC value of $16\text{--}64 \mu\text{g ml}^{-1}$; Table 2). These selected vegetable oils containing medium-chain fatty acids and long-chain fatty acids exhibited a twofold increase in activity as compared with the standard drug, fluconazole. However, the short-chain fatty acid, octyl-based imidazoline (**3a**) did not exhibit any activity towards the tested *Candida* strains. Therefore, all these tested fatty acid-based imidazolines can be well-exploited in different anti-*Candida* formulations.

The different fatty acid-based imidazolines were further screened against different cancer cell lines such as HeLa,

Table 2 Anti-*Candida* activity of fatty imidazolines **3a–h**

Compounds	Minimum inhibitory concentration (MIC, $\mu\text{g ml}^{-1}$)								
	<i>Candida albicans</i> MTCC 183	<i>Candida albicans</i> MTCC 3018	<i>Candida albicans</i> MTCC 3958	<i>Candida albicans</i> MTCC 7315	<i>Candida parapsilosis</i> MTCC 1744	<i>Candida albicans</i> MTCC 4748	<i>Candida albicans</i> MTCC 1637	<i>Candida albicans</i> MTCC 227	<i>Candida glabrata</i> MTCC 3019
3a	— ^a	—	—	—	—	—	—	—	—
3b	—	75	150	37.5	18.75	75	37.5	—	37.5
3c	—	300	75	37.5	18.75	18.75	—	—	37.5
3d	—	—	150	75	—	150	—	—	300
3e	4.68	75	18.75	18.75	18.75	150	37.5	37.5	—
3f	—	75	75	37.5	37.5	150	—	—	150
3g	—	300	150	75	37.5	75	—	—	18.75
3h	—	300	150	37.5	37.5	75	—	—	18.75
Imidazole	—	—	—	—	—	—	—	—	—
Fluconazole	32	32	64	32	16	32	32	32	64

^a No activity

Table 3 Cytotoxicity of fatty imidazolines **3a–h**

Compounds	IC ₅₀ values (μM)				
	HeLa	A549	MDA-MB-231	MCF-7	Neuro2a
3a	— ^a	—	—	44.09 ± 0.02	7.87 ± 0.01
3b	10 ± 0.05	12 ± 0.04	15 ± 0.02	8 ± 0.09	7.56 ± 0.03
3c	23.85 ± 0.04	19.62 ± 0.04	6.27 ± 0.03	50.2 ± 0.02	7.70 ± 0.03
3d	15 ± 0.05	74.28 ± 0.05	12.41 ± 0.06	—	8.38 ± 0.07
3e	34 ± 0.04	40 ± 0.03	43 ± 0.02	—	—
3f	15 ± 0.08	17.5 ± 0.05	17 ± 0.04	8.45 ± 0.07	6.61 ± 0.04
3g	—	29.71 ± 0.06	—	—	15.57 ± 0.03
3h	31.98 ± 0.02	8.24 ± 0.05	—	6.79 ± 0.06	—
Imidazole	—	—	—	—	—
Doxorubicin	0.509 ± 0.01	0.459 ± 0.02	0.91 ± 0.02	1.07 ± 0.02	1.04 ± 0.04

HeLa—human cervical cancer cell line, A549—human alveolar adenocarcinoma cell line; MDA-MB-231 and MCF-7—human breast adenocarcinoma cell line, Neuro2a—mouse neuroblastoma cell line

^a No activity

A549, MDA-MB-231, MCF7 and Neuro2a, and the results to this regard showed that they exhibited promising cytotoxicity for medium- and long-chain-based compounds such as **3b** (IC₅₀ values ranging between 7.56 and 15 μM), **3c** (IC₅₀ values ranging between 6.27 and 50.2 μM), **3d** (IC₅₀ value of 8.38 μM) and **3f** (IC₅₀ values ranging between 6.61 and 17.5 μM). However, the long-chain saturated-rich fatty acids-containing palm-based imidazoline (**3h**) showed excellent activity with IC₅₀ values ranging between 6.79 and 31.9 μM towards A549 and MCF 7 cell lines, while long-chain unsaturated-rich sunflower fatty acids-containing imidazoline (**3g**) exhibited good activity with IC₅₀ values ranging between 15.5 and 29.7 μM towards A549 and Neuro 2a cell lines (Table 3). However, the shorter chain fatty acid, octyl-based imidazoline (**3a**) exhibited promising activity with IC₅₀ value of 7.87 μM against the neuroblastoma cell line (Neuro 2a). Based on these results, it was suggested that all the above tested fatty acid-based imidazolines find application in a wide range of anti-cancer formulations.

Conclusions

In conclusion, the fatty imidazolines (**3a–h**) was synthesized under microwave conditions. Long-chain fatty acid-based imidazolines exhibited excellent anti-microbial activity as compared with the standard, neomycin. *Sterculia* containing cyclopropene-rich fatty acids-based imidazolines exhibited promising activity against *Candida albicans* MTCC 183 as compared with flucanazole, while the medium-chain fatty acid-based imidazolines exhibited good activity against the different *Candida* strains. Palm containing-long-chain saturated-rich fatty acids-based

imidazolines (**3h**) exhibited excellent cytotoxicity against A549 and MCF 7 cell lines. However, the shorter chain fatty acid, octyl-based imidazoline (**3a**) exhibited promising cytotoxicity against neuroblastoma cell lines (Neuro2a). These results suggest that the above fatty acid-based imidazolines can find possible application in wide range of pharmaceutical formulations.

Experimental section

Materials

All chemicals such as sodium hydroxide (NaOH), diethylenetriamine (DETA), calcium oxide (CaO) and solvents were procured from different commercial suppliers such as S.D. Fine Chemicals Limited, Mumbai, India and Avra Chemicals Pvt. Ltd, Hyderabad, India and were used without further purification. Pure fatty acids namely octanoic, dodecanoic, tetradecanoic and octadecanoic acids were commercially purchased from S.D. Fine Chemicals Limited, Mumbai, India, and mixture of fatty acids were obtained from vegetable oil sources such as coconut, sunflower and palm oil. *S. foetida* oil was obtained from *S. foetida* seeds obtained from Indian Institute of Chemical Technology (IICT) campus. Acid value and amine value of the synthesized imidazolines were determined according to the AOCS standard methods (Firestone, 2010).

Spectral analysis

¹H NMR and ¹³C NMR spectras were recorded on AVANCE 300 and 75 MHz, respectively, in CDCl₃.

Chemical shifts relative to TMS as internal standards were given as δ values in ppm. Infrared (IR) spectra were obtained on a 1600 FTIR Perkin-Elmer Spectrometer (Norwalk, CT) with a liquid film between NaCl cells. Mass spectrometry was recorded by electrospray ionization (ESI) on Shimadzu LC/MS instrument.

Determination of fatty acid composition

The composition of the fatty acids was determined using Agilent 6890N series Gas Chromatograph equipped with a flame ionization detector (FID); column, DB-225, 30 m \times 0.25 mm \times 0.2 μ m). The oven temperature was kept at 160 °C for 2 min and programmed from 160 to 180 °C at 6 °C/min, kept for 2 min at 180 °C and finally raised to 230 °C at 4 °C/min which was maintained at 230 °C for 25 min. The injector and detector temperatures were set at 250 °C.

General procedure for the synthesis of fatty imidazolines

Typical procedure for the synthesis of N-[2-(2-Alkyl-4,5-dihydro-imidazol-1-yl)-ethyl] amide of Sterculia fatty acid

Sterculia foetida fatty acids (2 mol), DETA (1 mol) and CaO were mixed and irradiated under a microwave power of 600 W at 100 °C for 4 min (Bajpai and Tyagi, 2008). The reaction mixture was allowed to cool to room temperature, dissolved in ethyl acetate and heated until boiling and filtered off while hot. The filtrate was concentrated under vacuum to dryness and passed through a silica gel column chromatography to obtain the corresponding N-[2-(2-alkyl-4,5-dihydro-imidazol-1-yl)-ethyl] amide of *Sterculia* fatty acid. The product was characterized for acid and amine values. A similar procedure was followed for the preparation of the fatty imidazolines of octyl (**3a**), dodecyl (**3b**), tetradecyl (**3c**), octadecyl (**3d**), coconut (**3f**), sunflower (**3g**) and palm fatty acids (**3h**). All these compounds were further characterized for FTIR, ^1H NMR, ^{13}C NMR and ESI-MS studies.

N-(2-(2-Heptyl-4,5-dihydro-1H-imidazol-1-yl)ethyl) octanamide (**3a**) Yield 87 %; $\text{C}_{20}\text{H}_{39}\text{N}_3\text{O}$; FTIR (cm^{-1} , neat) 3,397 (N–H str), 2,928 (CH_3 , C–H str), 1,711 (C=O str), 1,663 (C–N str), 715 ($(\text{CH}_2)_n$ skeletal, C–H str); ^1H NMR (CDCl_3 , 300 MHz): δ /ppm 0.89 (t, $J = 6.7$ Hz, $(\text{CH}_3)_2$, 6H), 1.26 (m, $-(\text{CH}_2)_8-$, 16H), 1.59 (m, $-(\text{CH}_2)_2-$, 4H), 1.96 (m, $-\text{CH}_2-\text{NH}-\text{CO}-$, 2H), 2.18 (t, $-\text{CH}_2-\text{CH}_2-\text{CO}-\text{NH}-$, 2H), 2.22–2.26 (m, $-\text{CH}_2$ attached to imidazole ring, 4H), 3.35–3.37 (m, imidazole ring protons, 4H), 6.10

(br, $-\text{CONH}-$, 1H); ^{13}C NMR (CDCl_3 , 75 MHz): δ /ppm 14.1, 21.5, 22.6, 25.8, 28.7, 29.5, 31.8, 36.5, 37.5, 48.1, 49.2, 56.3, 174.1; MS/ESI (m/z) Calcd: 337 [M+], found 338 [M + 1].

N-(2-(2-Undecyl-4,5-dihydro-1H-imidazol-1-yl)ethyl) dodecanamide (**3b**) Yield 89 %; $\text{C}_{28}\text{H}_{55}\text{N}_3\text{O}$; FTIR (cm^{-1} , neat): 3,389 (N–H str), 2,927 (CH_3 , C–H str), 1,715 (C=O str), 1,663 (C–N str), 716 ($(\text{CH}_2)_n$ skeleton, C–H str); ^1H NMR (CDCl_3 , 300 MHz): δ /ppm 0.87 (t, $J = 6.7$ Hz, $(\text{CH}_3)_2$, 6H), 1.27 (m, $-(\text{CH}_2)_{16}-$, 32H), 1.58 (m, $-(\text{CH}_2)_2-$, 4H), 1.97 (m, $-\text{CH}_2-\text{NH}-\text{CO}-$, 2H), 2.18 (t, $-\text{CH}_2-\text{CH}_2-\text{CO}-\text{NH}-$, 2H), 2.22–2.26 (m, $-\text{CH}_2$ attached imidazole ring, 4H), 3.33–3.60 (m, imidazole ring protons, 4H), 6.09 (br, $-\text{CONH}-$, 1H); ^{13}C NMR (CDCl_3 , 75 MHz): δ /ppm 14.1, 21.6, 22.7, 25.9, 25.8, 28.7, 29.3, 29.4, 29.9, 31.8, 36.6, 37.5, 49.3, 56.3, 174.2; MS/ESI (m/z) Calcd: 449 [M], found 450 [M + 1], 451 [M + 2].

N-(2-(2-Tridecyl-4,5-dihydro-1H-imidazol-1-yl)ethyl) tetradecanamide (**3c**) Yield 90 %; $\text{C}_{32}\text{H}_{63}\text{N}_3\text{O}$; FT-IR (cm^{-1} , neat): 3,387 (N–H str), 2,928 (CH_3 , C–H str), 1,711 (C=O str), 1,661 (C–N str), 715 ($(\text{CH}_2)_n$ skeleton, C–H str); ^1H NMR (CDCl_3 , 300 MHz): δ /ppm 0.88 (t, $J = 6.7$ Hz, $(\text{CH}_3)_2$, 6H), 1.27 (m, $-(\text{CH}_2)_{20}-$, 40H), 1.59 (m, $-(\text{CH}_2)_2-$, 4H), 1.98 (m, $-\text{CH}_2-\text{NH}-\text{CO}-$, 2H), 2.19 (t, $-\text{CH}_2-\text{CH}_2-\text{CO}-\text{NH}-$, 2H), 2.22–2.27 (m, $-\text{CH}_2$ attached imidazole ring, 4H), 3.33–3.50 (m, imidazole ring protons, 4H), 6.17 (br, $-\text{CONH}-$, 1H); ^{13}C NMR (CDCl_3 , 75 MHz): δ /ppm 14.0, 22.6, 25.6, 26.0, 29.3, 29.6, 31.8, 36.5, 37.6, 48.1, 49.1, 56.2, 174.2; MS/ESI (m/z) Calcd: 505 [M+], found 506 [M + 1], 528 [M + Na].

N-(2-(2-Heptadecyl-4,5-dihydro-1H-imidazol-1-yl)ethyl) stearamide (**3d**) Yield 91 %; $\text{C}_{40}\text{H}_{79}\text{N}_3\text{O}$; FT-IR (cm^{-1} , neat): 3,397 (N–H str), 2,928 (CH_3 , C–H str), 1,711 (C=O str), 1,663 (C–N str), 715 ($(\text{CH}_2)_n$ skeleton, C–H str); ^1H NMR (CDCl_3 , 300 MHz): δ /ppm 0.88 (t, $J = 6.7$ Hz, $(\text{CH}_3)_2$, 6H), 1.27 (m, $-(\text{CH}_2)_{28}-$, 56H), 1.59 (m, $-(\text{CH}_2)_2-$, 4H), 1.97 (m, $-\text{CH}_2-\text{NH}-\text{CO}-$, 2H), 2.18 (t, $-\text{CH}_2-\text{CH}_2-\text{CO}-\text{NH}-$, 2H), 2.23–2.27 (m, $-\text{CH}_2$ attached imidazole ring, 4H), 3.35–3.50 (m, imidazole ring protons, 4H), 6.18 (br, $-\text{CONH}-$, 1H); ^{13}C NMR (CDCl_3 , 75 MHz): δ /ppm 14.1, 21.8, 25.6, 26.8, 29.7, 31.7, 36.7, 37.8, 48.2, 49.3, 56.0, 174.1; MS/ESI (m/z) Calcd: 617 [M+], found 618 [M + 1].

N-[2-(2-Alkyl-4, 5-dihydro-imidazol-1-yl)-ethyl] amide of *Sterculia* fatty acid (**3e**) Yield 85 %; FT-IR (cm^{-1} , neat) 3,397 (N–H str), 2,928 (CH_3 , C–H str), 1,711 (C=O str), 1,664 (C–N str), 716 ($(\text{CH}_2)_n$ skeleton, C–H str); ^1H NMR (CDCl_3 , 300 MHz): δ /ppm 0.78 (s, 2H,

cyclopropene ring proton), 0.88 (t, $J = 6.7$ Hz, $(CH_3)_2$, 6H), 1.26 (m, $-(CH_2)_n$), 1.62 (m, $-(CH_2)_2$, 4H), 1.81 (m, $-CH_2-NH-CO-$, 2H), 2.18 (t, $-CH_2-CH_2-CO-NH-$, 2H), 2.74 (m, $-CH_2$ attached imidazole ring, 4H), 3.34 (m, imidazole ring protons, 4H), 5.34 (m, $-CH=CH-$, 2H), 6.16 (br, $-CONH-$, 1H); ^{13}C NMR ($CDCl_3$, 75 MHz): 8.0, 14.1, 21.6, 23.5, 26.2, 28.4, 28.6, 29.6, 29.9, 31.7, 35.8, 37.2, 49.2, 55.8, 57.5, 112.7, 113.8, 174.6; MS/ESI (m/z) Calcd: 637 (sterculic, $[M+]$), found 660 (sterculic, $[M + Na]$).

N-[2-(2-Alkyl-4, 5-dihydro-imidazol-1-yl)-ethyl] amide of coconut fatty acid (**3f**) Yield 89 %; FT-IR (cm^{-1} , neat): 3,397 (N-H str), 2,928 (CH_3 , C-H str), 1,711 ($-C=O$ str), 1,663 (C-N str), 715 ($(CH_2)_n$ skeleton, C-H str); 1H NMR ($CDCl_3$, 300 MHz): δ/ppm 0.87 (t, $J = 6.7$ Hz, $(CH_3)_2$, 6H), 1.25 (m, $-(CH_2)_n$), 1.61 (m, $-(CH_2)_2$, 4H), 1.77 (m, $-CH_2-NH-CO-$, 2H), 2.17 (t, $-CH_2-CH_2-CO-NH-$, 2H), 2.67–2.79 (m, $-CH_2$ attached imidazole ring, 4H), 3.20–3.32 (m, imidazole ring protons, 4H), 5.30–5.38 (m, $-CH=CH-$, 2H), 6.13 (br, $-CONH-$, 1H); ^{13}C NMR ($CDCl_3$, 75 MHz): 14.1, 21.7, 23.6, 26.1, 28.5, 29.8, 31.6, 37.2, 49.2, 55.8, 134.5, 135.6, 174.3; MS/ESI (m/z) Calcd: 449 $[M+]$, found 450 $[M + 1]$.

N-[2-(2-Alkyl-4, 5-dihydro-imidazol-1-yl)-ethyl] amide of sunflower fatty acid (**3g**) Yield 86 %; FT-IR (cm^{-1} , neat): 3,395 (N-H str), 2,928 (CH_3 , C-H str), 1,711 ($-C=O$ str in amide), 1,663 (C-N str), 715 ($(CH_2)_n$ skeleton, C-H str); 1H NMR ($CDCl_3$, 300 MHz): δ/ppm 0.88 (t, $J = 6.7$ Hz, $(CH_3)_2$, 6H), 1.26 (m, $-(CH_2)_n$), 1.58 (m, $-(CH_2)_2$, 4H), 1.82 (m, $-CH_2-NH-CO-$, 2H), 2.18 (t, $-CH_2-CH_2-CO-NH-$, 2H), 2.70–2.79 (m, $-CH_2$ attached imidazole ring, 4H), 3.20–3.32 (m, imidazole ring protons, 4H), 5.30–5.35 (m, $-CH=CH-$, 2H), 6.13 (br, $-CONH-$, 1H); ^{13}C NMR ($CDCl_3$, 75 MHz): 14.1, 21.3, 22.8, 23.7, 26.5, 28.6, 29.7, 29.9, 32.0, 37.5, 49.5, 55.3, 134.2, 135.6, 174.1; MS/ESI (m/z): Calcd: 613 (18:1, $[M+]$), 609 (18:2, $[M+]$), found 636 (18:1, $[M + Na]$), 632 (18:2, $[M + Na]$).

N-[2-(2-Alkyl-4, 5-dihydro-imidazol-1-yl)-ethyl] amide of palm fatty acid (**3h**) Yield 89 %; FT-IR (cm^{-1} , neat): 3,397 (N-H str), 2,928 (CH_3 , C-H str), 1,712 ($-C=O$ str), 1,662 (C-N str), 716 ($(CH_2)_n$ skeleton, C-H str); 1H NMR ($CDCl_3$, 300 MHz): δ/ppm 0.88 (t, $J = 6.9$ Hz, $(CH_3)_2$, 6H), 1.25 (m, $-(CH_2)_n$), 1.61 (m, $-(CH_2)_2$, 4H), 2.00 (m, $-CH_2-NH-CO-$, 2H), 2.30 (t, $-CH_2-CH_2-CO-NH-$, 2H), 2.69–2.77 (m, $-CH_2$ attached imidazole ring, 4H), 3.20–3.32 (m, imidazole ring protons, 4H), 5.31–5.37 (m, $-CH=CH-$, 2H), 6.13 (br, $-CONH-$, 1H); ^{13}C NMR ($CDCl_3$, 75 MHz): 14.1, 18.4, 22.6, 23.8, 25.9, 29.1, 29.6, 31.8, 37.6, 49.5, 55.2, 134.1, 135.6, 174.2; MS/ESI (m/z): Calcd 561 (16:0, $M+$), 589 (16:0 + 18:0) found 562 (16:0, $[M + H]$), 606 $[16:0 + 18:0]$.

Biological evaluation

The prepared fatty imidazolines were evaluated for antimicrobial activity against different Gram-positive and Gram-negative bacteria such as *S. aureus* MTCC 96, *S. aureus* MLS16 MTCC 2940 and *P. aeruginosa* MTCC 2453 and different *Candida* strains such as *Candida albicans* MTCC 183, *Candida albicans* MTCC 3018, *Candida albicans* MTCC 3958, *Candida albicans* MTCC 7315, *Candida parapsilosis* MTCC 1744, *Candida albicans* MTCC 4748, *Candida albicans* MTCC 1637, *Candida albicans* MTCC 227 and *Candida glabrata* MTCC 3019 using the well-diffusion method (Amsterdam, 1996). The pathogenic bacterial and *Candida* reference strains were seeded on the surface of the media petri plates, containing Muller–Hinton agar with 0.1 ml of previously prepared microbial suspensions individually containing 1.5×10^8 cfu ml^{-1} (equal to 0.5 McFarland). Wells of 6.0 mm diameter were prepared in the media petri plates using a cork borer, and the synthesized compounds at a dose range of 300–1.4 μg well $^{-1}$ were added in each well under sterile conditions in a laminar air flow chamber. Standard antibiotic solutions of neomycin and fluconazole at a dose range of 300–1.4 μg well $^{-1}$ were used as positive controls, and the well containing methanol served as negative control. Imidazole was also run in parallel as a reference. The plates were incubated for 24 h at 30 °C, and the well containing the least concentration showing the inhibition zone was considered as the minimum inhibitory concentration. All experiments were carried out in duplicates, and mean values are represented.

Cytotoxicity of the products were assessed against a panel of different cancer cell lines obtained from the American Type Culture Collection (ATCC), Manassas, VA, USA, such as HeLa derived from human cervical cancer cells (ATCC No. CCL-2), A549 derived from human lung adenocarcinoma epithelial cells (ATCC No. CCL-185) and MDA-MB-231 derived from human breast adenocarcinoma cells (ATCC No. HTB-26), MCF-7 derived from human breast adenocarcinoma cells (ATCC No. HTB-22) and Neuro2a derived from mouse neuroblastoma cell line (ATCC No. CCL-131) using the MTT colorimetric assay (Mosmann, 1983), which is based on the measurement of in vitro growth of tumour cell lines in 96-well plates by cell-mediated reduction in tetrazolium salt to water insoluble formazan crystals according to the literature procedures using doxorubicin as a standard and imidazole as a reference. After 48 h incubation, the cells were subjected to MTT colorimetric assay (5 mg ml^{-1} MTT). The effect of the different test compounds on the viability of tumour cell lines was measured at the wavelength of 540 nm on a multimode reader (Infinite® M200, Tecan, Switzerland). Dose–response curves were plotted

for the test compounds and controls after correction by subtracting the background absorbance from that of the blanks. The anti-tumour potency of the compounds indicated by the IC_{50} values (50 % inhibitory concentration) were calculated from the plotted absorbance data for the dose–response curves. IC_{50} values (in μM) are expressed as the average of three independent experiments, which was calculated using the statistical tool available in Microsoft Excel program.

References

- Amsterdam D (1996) Susceptibility testing of antimicrobials in liquid media. In: Lorian V (ed) Antibiotics in laboratory medicine, 4th edn. Williams and Wilkins, Baltimore
- Bajpai D, Tyagi VK (2007) Synthesis of fatty imidazolines based on palm fatty acids and diethylenediamine through microwave irradiation and their characterization. *Heterocycl Commun* 13:377–380
- Bajpai D, Tyagi VK (2008) Microwave synthesis of cationic fatty imidazolines and their characterization. *J Surfactants Deterg* 11:79–87
- Baltork M, Alibeik MA (2003) Microwave-assisted facile and convenient synthesis of imidazolines. *Bull Korean Chem Soc* 24:1354–1356
- Firestone D (2010) Official methods and recommended practices of the Americal Oil Chemist's Society, 5th edn. AOCS Press, Champaign (Methods Te 2a-64 and Tf 2b-64)
- Grammitt MR, Katrizky AR, Boulton AJ (1989) In *Advances in heterocyclic chemistry*. Academic, New York, p 241
- Ismail AA, Hafiz AA, EI-Awady MY, Habib AO (2010) Some imidazoline derivative as corrosion inhibitors. *J Surfactants Deterg* 13:247–254
- Kanjilal S, Sunitha S, Reddy PS, Kumar KP, Murthy USN, Prasad RBN (2009) Synthesis and evaluation of micellar properties and antimicrobial activities of imidazole-based surfactants. *Eur J Lipid Sci Technol* 111:941–948
- Karlheinz H (2000) Fats and oils as oleochemical raw materials. *Pure Appl Chem* 72:1255–1264
- Khabnadideh S, Rezaei Z, Khalafi-Nezhad A, Bahrinajafi R, Mohamadi R, Farrokhrooz AA (2003) Synthesis of N-alkylated derivatives of imidazole as antibacterial agents. *Bioorg Med Chem Lett* 13:2863–2865
- Miller DK, Griffiths E, Lenard J, Firestone RA (1983) Cell killing by lysosomotropic detergents. *J Cell Biol* 97:1841–1851
- Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival; application to proliferation and cytotoxicity assays. *J Immunol Methods* 65:55–63
- Mukherjee A, Kumar S, Seth M, Bhaduri AP (1989) Synthesis of 1-methyl-4-nitro-5-substituted imidazole and substituted imidazolothiazole derivatives as possible antiparasitic agents. *Ind J Chem* 28B:391
- Norman SM, Bennett RD, Ploing SM, Maier VP, Nelson MD (1986) Paclobutrazol inhibits abscisic acid biosynthesis in *Cercospora rosicola*. *Plant Physiol* 80:122–125
- Palou RL, De Paz G, Marin-Cruz J, Zepeda LG (2003) Synthesis of long chain 2-alkyl-1-(2-hydroxy ethyl)-2-imidazolines under microwave in solvent free conditions. *Synlett* 12:1847–1849
- Popa I, Lupu A, Parausanu V, Scorteanu G (2001) Ammonium quaternary salts of 1, 2 disubstituted imidazoline derivatives. Presented in 12th international conference on Chemistry and Chemical Engineering
- Wilkinson CF, Hetnarski K (1974) Structure-activity relationships in the effects of 1-alkylimidazoles on microsomal oxidation in vitro and in vivo. *Biochem Pharmacol* 23:2377–2386